Dr Jack Tan
President of Asian Pacific Society of Cardiology
Dr Zhou Ning
Deputy Chief Physician, Department of Cardiovascular Medicine, Tongji Hospital, China

COVID-19 and the Heart, Experience from Front Line

COVID-19 is a fast-moving pandemic. The infection has a mortality rate of 3-6%. Patients with underlying CVD are at higher risk of contracting COVID-19 and have a worse prognosis.
Our experts from Wuhan China and Singapore have shared clinical experiences from frontline China on management of COVID-19 patients with underlying heart disease. Topics include:

  1. Diagnosis to management of COVID-19 patients with underlying CVD: Learnings from China
  2. COVID-19 and Anti-hypertensive Drugs
  3. Clinical Case sharing – experience from Singapore

Professor Zhou Ning – Clinical Characteristics and Management of COVID-19 Patients

Professor Koji Hasegawa – COVID-19 and Anti-hypertensive Drugs

Dr Ling Li Min – Clinical Case Sharing – Experiences from Singapore

Panel discussion

Updates from Leading Experts

STRONG-HF: Post-discharge Heart Failure Management and Implementation of GDMT Heart Failure Therapy

Prof Alexandre Mebazaa shares the key results and highlights from the STRONG-HF study that assessed the safety, tolerability of optimization of guideline directed medical therapy. [...]


CANVAS study: NT-proBNP and CVD risk reduction

Can you give us a short description of the CANVAS program? The CANVAS program was a set of two trials, whose goal was to evaluate the role of an SGLT2...

1 July 2021
Dr James L Januzzi